FRCS ORL-HNS Exam Preparation | #1 Best Study Resources

Q: What is the FRCS free trial?

The FRCS free trial gives you 50 questions for 1 week, with account creation handled during checkout.

Q: How many questions are in the FRCS (ORL-HNS) Section 1 bank?

The FRCS (ORL-HNS) Section 1 question bank contains >4,200 SBA questions and continues to grow.

Q: Are mock papers included in subscriptions?

No — mock papers are a separate purchase and are not included in subscriptions. Subscriptions cover the question bank, analytics, and repeat cycles.

FRCS (ORL-HNS) Section 1 question bank landing page with analytics, spaced repetition, timed practice, direct checkout plans, a 1-week free trial, and a 5-question preview.

5-question preview

Try the SBA style + explanations (FRCS Section 1)

Quick way to check question style, pacing, and explanation quality — before you commit to a plan.

Updated preview 5 questions

FRCS (ORL-HNS) Section 1 — Free Sample Quiz

Gauge Your Readiness for the FRCS (ORL-HNS) Section 1 Exam

Curious about what the FRCS (ORL-HNS) Section 1 exam will entail? Try our 5-question preview quiz to get a taste of the actual exam. This brief quiz will help you identify your strengths and areas for improvement. Ready to challenge yourself?

Complete this quick quiz and if you find it beneficial, sign up for our 50-question free trial to further enhance your exam preparation.

A 38-year-old man presents with 9 months of progressive loss of peripheral vision and occasional headaches. MRI demonstrates a 3.2 cm non-functioning pituitary macroadenoma with suprasellar extension compressing and elevating the optic chiasm. Endocrine assessment shows panhypopituitarism, and he has been commenced on appropriate hormone replacement. Combined endoscopic transsphenoidal resection is recommended.

During counselling he asks, "What is the main thing this operation is trying to achieve?"

Which ONE of the following statements BEST reflects the primary goal of surgery that should be emphasised?

To eliminate the need for further MRI or endocrine follow-up once gross total resection is achieved

To prevent future tumour growth by routinely administering adjuvant radiotherapy after resection

To restore normal pituitary hormone secretion in the majority of patients with established panhypopituitarism

To provide a permanent cure for his headaches, even though the pattern is non-specific and migrainous

To decompress the optic apparatus to preserve or improve vision, accepting that pituitary function may not normalise

Tutor-style explanation

Correct answer: E.

Explanation:
Why this option is correct:
For a non-functioning pituitary macroadenoma producing chiasmal compression and visual field loss, the principal goal of surgery is mechanical decompression of the optic apparatus to preserve or improve vision. While resection may reduce further mass effect and reduce the risk of future growth, and endocrine function can sometimes improve, visual preservation is the dominant and most predictable benefit. Patients with established panhypopituitarism are unlikely to recover full hormonal function, so it is safest to counsel that visual outcomes, not endocrine cure, are the primary aim.

Why the other options are wrong:
Restoration of normal pituitary hormone secretion in a patient with established panhypopituitarism is uncommon, particularly with large non-functioning macroadenomas. Although some recovery of individual axes can occur after decompression, it is not sufficiently reliable to be framed as the main aim of surgery, and lifelong hormone replacement is frequently required.

Routine adjuvant radiotherapy for all macroadenomas after resection is not standard practice. Radiotherapy is generally reserved for progressive or residual tumours where further surgery is not feasible or would be high risk. The primary intervention in this case is surgical decompression, with imaging surveillance and selective use of adjuvant treatment.

Headache may improve after resection but is a non-specific symptom with multifactorial aetiology. Even in series where headaches frequently improve postoperatively, the response cannot be guaranteed, and it should not be presented as the principal aim of surgery, particularly when the pattern is migrainous rather than clearly related to intracranial pressure or mass effect.

Eliminating the need for further MRI or endocrine follow-up is unrealistic. Even after an apparently gross total resection, there remains a risk of residual microscopic disease and later recurrence, and endocrine function may evolve over time. Long-term radiological and hormonal surveillance is a standard component of safe pituitary tumour management and cannot be dispensed with following surgery.

Further Reading:
Moussazadeh N, Prabhu V, Bander ED, et al. Visual outcomes after endoscopic endonasal pituitary adenoma resection: systematic review and meta-analysis. Pituitary. 2018;21(3):277-291. (pubmed.ncbi.nlm.nih.gov)
Ziu M, Dunn IF, Hess C, et al. CNS guideline on posttreatment follow-up evaluation of nonfunctioning pituitary adenomas. Neurosurgery. 2016;79(4):E541-E543. (pubmed.ncbi.nlm.nih.gov)
Cappabianca P, Cavallo LM, Colao A, et al. Endoscopic endonasal transsphenoidal approach: outcome analysis of 228 pituitary adenomas. Neurosurgery. 2009;55(2):357-367. (pubmed.ncbi.nlm.nih.gov)

Additional Concepts:
• The likelihood of visual recovery after chiasmal decompression depends on the duration and severity of preoperative deficit and on the degree of optic atrophy. Early intervention in progressive field loss generally yields better outcomes than surgery undertaken late in the course of visual compromise.
• Panhypopituitarism in patients with non-functioning macroadenomas often reflects chronic compression and vascular compromise of the normal gland. Even after decompression, ischaemic or atrophic tissue may not recover, so robust preoperative counselling about the need for ongoing hormone replacement is essential.
• Adjuvant radiotherapy is typically reserved for progressive residual tumour, particularly if it threatens the optic apparatus or cavernous sinus structures and further surgery is not feasible. Its use must be weighed against the risk of inducing or worsening hypopituitarism and a small long-term risk of secondary neoplasia.
• Management of pituitary tumours is best delivered through a dedicated pituitary multidisciplinary team incorporating endocrinology, neurosurgery, otolaryngology, neuroradiology and ophthalmology, to optimise decision-making around timing of surgery, extent of resection and long-term surveillance.

A 50-year-old woman with established primary Sjögren's syndrome presents to the ENT clinic with her third episode in 18 months of painful swelling of both parotid glands. The swelling is most marked during meals and typically settles over several hours but leaves residual tenderness for days. She denies fevers, weight loss or night sweats. Examination between attacks shows symmetrically enlarged but soft parotid glands without focal masses, facial nerve weakness or cervical lymphadenopathy. Intra-oral examination confirms poor salivary pooling but no purulence from the Stensen ducts.

Her rheumatologist reports stable systemic disease on hydroxychloroquine. She has already maximised conservative measures including aggressive hydration, sugar-free chewing gum, pilocarpine and NSAIDs, with limited benefit. High-resolution ultrasound of both parotids shows multiple punctate hypoechoic foci and segmental ductal narrowing, consistent with chronic sialadenitis in Sjögren's syndrome. No calculi or focal solid lesions are identified.

She asks specifically whether there is an interventional procedure that might reduce the frequency and severity of these painful flares while preserving salivary function.

Which ONE of the following is the MOST appropriate next step?

Ultrasound-guided fine-needle aspiration cytology of both parotid glands

Interventional sialendoscopy with ductal dilatation and saline plus corticosteroid irrigation of both parotid ducts

Elective bilateral superficial parotidectomies with facial nerve monitoring

Observation only with continuation of current conservative measures

Low-dose external-beam radiotherapy to both parotid glands for pain control

Tutor-style explanation

Correct answer: B.

Explanation:
Why this option is correct:
Interventional sialendoscopy with duct dilatation and lavage, often combined with intraductal corticosteroid irrigation, directly addresses the obstructive–inflammatory ductal pathology that characterises Sjögren-associated sialadenitis. Endoscopic techniques allow visualisation and mechanical dilatation of strictures, disruption of mucous plugs and delivery of anti-inflammatory agents along the duct system, while preserving the gland. Several retrospective series have demonstrated substantial reductions in the frequency of swelling episodes, improvements in pain scores and, in some patients, modest improvements in salivary flow after sialendoscopy in Sjögren's syndrome. This minimally invasive approach is therefore an appropriate next step after failure of optimal conservative measures in a patient without imaging evidence of neoplasia.

Why the other options are wrong:
Bilateral superficial parotidectomy would expose the patient to significant morbidity, including a substantial risk of facial nerve palsy, Frey syndrome and cosmetic contour deformity. In Sjögren's syndrome, surgery is generally reserved for severe refractory pain or recurrent parotitis that has failed less invasive measures such as sialendoscopy, or for proven or strongly suspected malignancy. It is excessive as a first-line interventional option in a patient with diffuse, non-mass-forming disease.

External-beam radiotherapy is not indicated in benign inflammatory salivary gland disease and is particularly undesirable in Sjögren's syndrome, where further reduction in salivary function would compound xerostomia and dental morbidity. The potential late risks of radiation, including secondary malignancy and soft-tissue fibrosis, outweigh any speculative analgesic benefit.

Observation alone with continuation of current conservative measures ignores the fact that the patient has already optimised non-invasive management and remains significantly symptomatic. At this stage, a step-up to a minimally invasive interventional option is reasonable and supported by available outcome data.

Fine-needle aspiration cytology may be appropriate if there is a focal mass or asymmetric persistent enlargement raising concern for lymphoma or another neoplasm. In this scenario, imaging shows no focal lesions and the clinical picture is of episodic, meal-related swelling. FNAC would not alter management and does not address the underlying ductal pathology.

Further Reading:
Leventer-Roberts M, Amir E, Eliashar R, et al. Sialendoscopy enhances saliva production of parotid glands in primary Sjögren syndrome patients. Quintessence Int. 2023;54(3):234–240. (pubmed.ncbi.nlm.nih.gov)
Capaccio P, Gaffuri M, Rossi V, et al. Combined interventional sialendoscopy and intraductal steroid therapy for recurrent sialadenitis in Sjögren's syndrome: results of a pilot trial. Clin Otolaryngol. 2017;42(5):1031–1036. (pubmed.ncbi.nlm.nih.gov)
Jouzdani E, Capaccio P, Ariaudo L, et al. Complications of sialendoscopy in patients with Sjögren syndrome. Laryngoscope. 2017;127(9):2068–2073. (pubmed.ncbi.nlm.nih.gov)

Additional Concepts:
• Sialendoscopy in Sjögren's syndrome often reveals pale, avascular duct walls with multiple strictures and occasional mucous plugs; recognising this endoscopic appearance helps distinguish autoimmune sialadenitis from purely lithiasic disease.
• Although sialendoscopy is minimally invasive, the risk of ductal perforation, infection and transient post-procedural swelling is higher in Sjögren patients because of the friable, stenotic ducts; careful technique and judicious patient selection are therefore important.
• Improvement after sialendoscopy in Sjögren's syndrome tends to be greatest in patients with earlier-stage disease, where ducts are narrowed but not completely obliterated and some functional acini remain, emphasising the value of intervening before end-stage fibrosis.
• When planning bilateral sialendoscopy, it is often prudent to stage procedures rather than treat both parotids at once in patients with marginal salivary reserve, so that an unexpected complication on one side does not leave the patient acutely anhidrotic.

A 6-week-old ex-preterm infant (corrected gestational age 38 weeks) weighing 4 kg is listed for bedside flexible nasendoscopy to evaluate suspected laryngomalacia. The anaesthetist suggests using the same topical lignocaine regimen as for older infants, based on a maximum total dose of 3 mg/kg plain lignocaine, delivered via a 4% metered-dose spray (10 mg per actuation).

From the perspective of safe pharmacology in this age group, which ONE of the following statements BEST reflects appropriate modification of lignocaine dosing in such a young infant?

Lignocaine dosing for topical airway anaesthesia should be based solely on gestational age rather than weight in the first six months of life

The calculated maximum total dose should be reduced by roughly one-third in infants under 6 months because of reduced protein binding and hepatic clearance

The maximum lignocaine dose can be increased to 7 mg/kg in neonates because their larger volume of distribution lowers serum concentrations

The full 3 mg/kg maximum dose can be used because systemic absorption from nasal and pharyngeal mucosa is negligible in infants

Lignocaine should be completely avoided in infants under 6 months and replaced with prilocaine, which has no risk of systemic toxicity in this age group

Tutor-style explanation

Correct answer: B.

Explanation:
Why this option is correct: Neonates and young infants have immature hepatic metabolism and lower concentrations of α1-acid glycoprotein, resulting in reduced protein binding and slower clearance of amide local anaesthetics such as lignocaine. Many paediatric anaesthesia recommendations therefore advise a dose reduction of around 30% for amide local anaesthetics in infants under 6 months compared with older children. Applying this principle means that a nominal 3 mg/kg ceiling should be scaled down in very young infants, and clinicians should aim for the lowest effective dose, often well below the calculated maximum, especially when using topical preparations with variable absorption.

Why the other options are wrong: The suggestion that the full 3 mg/kg limit can be used without modification ignores the altered pharmacokinetics and pharmacodynamics in early infancy; systemic absorption from airway mucosa is clinically relevant and small babies have less physiological reserve for toxicity. The statement proposing complete avoidance of lignocaine and substitution with prilocaine is incorrect and unsafe; prilocaine itself can cause serious toxicity including methaemoglobinaemia, and lignocaine remains the standard agent when used at appropriately reduced doses. The option advocating an increased maximum of 7 mg/kg in neonates misapplies data from controlled bronchoscopy studies and overlooks the fact that larger volumes of distribution do not negate the higher free fraction and reduced clearance in infants; it is not an appropriate routine ceiling in this age group. The suggestion to base dosing solely on gestational age rather than weight is physiologically unsound, as systemic exposure is fundamentally weight-dependent; while prematurity is relevant, both age and weight must be considered in dose calculations.

Further Reading:
Amitai Y, Zylber-Katz E, Avital A, et al. Serum lidocaine concentrations in children during bronchoscopy with topical anesthesia. Chest. 1990;98(6):1370-1373. (pubmed.ncbi.nlm.nih.gov)
Sitbon P, Laffon M, Lesage V, et al. Lidocaine plasma concentrations in pediatric patients after providing airway topical anesthesia from a calibrated device. Anesth Analg. 1996;82(5):1003-1006. (pubmed.ncbi.nlm.nih.gov)
Walters E, Wurster Ovalle V, Yin S, Dribin T. Infant with status epilepticus secondary to systemic lidocaine toxicity from topical application. BMJ Case Rep. 2020;13(1):e233119. (pmc.ncbi.nlm.nih.gov)

Additional Concepts:
• Neonates and young infants have lower concentrations of α1-acid glycoprotein, which increases the free (pharmacologically active) fraction of amide local anaesthetics at a given total plasma concentration and therefore increases toxicity risk.
• Immature hepatic enzyme systems and reduced hepatic blood flow in early infancy prolong the elimination half-life of lignocaine, so repeated dosing or high single doses can lead to accumulation and delayed toxicity.
• Intralipid (intravenous lipid emulsion) therapy is now an accepted treatment for severe local anaesthetic systemic toxicity, particularly when there is cardiovascular instability or refractory seizures, and should be immediately available wherever high-dose local anaesthetics are used.
• For very young infants requiring airway assessment, many centres favour techniques that minimise or avoid topical local anaesthetic, such as light general anaesthesia with spontaneous ventilation, in order to reduce reliance on drugs with narrow safety margins.

A 63-year-old man with poorly controlled type 2 diabetes presents with 36 hours of severe retro-orbital pain, numbness of the right cheek, and epistaxis. Nasal endoscopy shows only mild oedema of the middle meatus. His C-reactive protein is 34 mg/L and ketones are negative. Because of the minimal endoscopic findings but high clinical suspicion of acute invasive fungal rhinosinusitis (AIFRS), an urgent MRI of the paranasal sinuses is performed with gadolinium, fat suppression and diffusion-weighted sequences. The report notes complete lack of enhancement of the right middle turbinate with surrounding mucosal thickening but no bony erosion. Which of the following imaging findings is MOST specific for early angio-invasive mucormycosis and therefore should trigger immediate surgical debridement?

Non-enhancing nasal turbinate on fat-suppressed post-contrast T1-weighted MRI (“black turbinate sign”)

Hyperattenuating inspissated secretions within the maxillary sinus on non-contrast CT bone algorithm

Diffusion restriction in the sphenoid sinus on DWI sequences

Fluid–fluid level within the frontal sinus on sagittal T2-weighted MRI

Complete opacification of the ethmoid labyrinth with lamina papyracea dehiscence on coronal CT

Tutor-style explanation

The “black turbinate sign” describes devascularised nasal turbinate mucosa that fails to enhance on fat-suppressed, gadolinium-enhanced T1 MRI and is an early, relatively specific marker of angio-invasive fungal rhinosinusitis, particularly mucormycosis. It reflects vascular thrombosis and tissue necrosis before overt bone destruction occurs. pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.govradiopaedia.orgsciencedirect.com

Hyperattenuating secretions on CT (option b) can be seen with allergic fungal rhinosinusitis or chronic inspissated mucus and lack specificity for angio-invasion. pmc.ncbi.nlm.nih.gov

Diffusion restriction (option c) may occur once infarction develops but is less sensitive than contrast-enhancement loss and is not specific for mucormycosis. insightsimaging.springeropen.com

Fluid–fluid levels (option d) signify haemorrhage or acute sinusitis of varied aetiologies and are non-specific. pmc.ncbi.nlm.nih.gov

Ethmoidal opacification with lamina papyracea erosion (option e) represents later bony invasion; at this stage morbidity is higher, and earlier signs should already have prompted treatment. insightsimaging.springeropen.com

How to use this preview for the best signal

Treat it like a mini timed set: answer, review the rationale, then note the themes you would target next. Paid plans unlock the full bank, analytics, and repeat cycles.

Best low-friction next step

Start the 1-week FRCS free trial to unlock 50 questions and create your account during checkout. If you already know you want full access, use any paid plan button on this page.

Start free 1-week trial Get 6-month access Open the app (free questions)

Works on mobile and desktop. No install required.

What is Section 1?

What FRCS (ORL-HNS) Section 1 tests — and how to revise efficiently

FRCS (ORL-HNS) Section 1 is a written SBA-style assessment across core otolaryngology subspecialties and high-yield decision-making. The fastest progress usually comes from a repeat loop of targeted questions, clear explanations, and retesting weak themes.

If you are searching for FRCS ORL-HNS Section 1 SBA questions or Part 1 questions, this is built as a revision bank that helps you spot weak areas, then fix them with repeat cycles.

Coverage across ENT subspecialties

Build confidence across the breadth of ENT, then target weak themes with analytics.

Otology & Audiovestibular Rhinology & Skull Base Laryngology & Airway Head & Neck Oncology Paediatric ENT Facial Plastics Emergency ENT Basic science & evidence

Start free 1-week trial View plans Open the app

What you get

A Section 1 system: practise → review → repeat (without the noise)

Use the question bank to build knowledge and exam sense, then lock it in with spaced review. Built for consistent revision — whether you are early in prep or in the final sprint.

>4,200 SBA questions for FRCS (ORL-HNS) Section 1 practice.
Custom quizzes by topic, weak areas, and mixed sets.
Analytics to track performance by subspecialty and improvement week to week.
Spaced repetition that resurfaces flagged questions at the right time.

Start free 1-week trial Choose a plan Open the app

Trusted by >2,000 ENT trainees.

FRCS (ORL-HNS) Section 1 analytics illustration showing weak-area targeting

Mock papers

Timed mock papers for Section 1 rehearsal

Use mock papers to train exam-day pacing, stamina, and decision-making under pressure — especially in your final 2 to 6 weeks.

Important:

Mock papers are available as a separate purchase and are not included in subscriptions. Subscriptions cover the question bank, analytics, and repeat cycles.

Go to mock papers Start free 1-week trial View plans

Why not generic banks?

A faster path to marks than random drilling

Most candidates do not need more questions — they need a repeatable loop that targets weak themes and trains pacing.

Generic banks / recalls	OtoPrep FRCS (ORL-HNS) Section 1
Mixed difficulty without direction	Analytics highlight weak subspecialties so you study what moves your score
One-pass learning (easy to forget)	Flag → revisit → retain with spaced repetition built into your workflow
Hard to measure progress	Track improvement week to week and retest weak areas intentionally
Mocks unclear / bundled elsewhere	Mock papers are available separately (not included in subscriptions)

Start free 1-week trial See plans Mock papers

Free tips

Get weekly Section 1 revision tips

Short, practical tips to improve timing, accuracy, and review loops — plus occasional feature updates.

Get your free tips + revision plan

Tell us what you are preparing for and we’ll send you targeted help.

Name Email Phone

Include your country code (e.g. +14155552671). If you're outside the list, type the full number starting with + (e.g. +4915112345678).

Which exam(s) are you preparing for?

FRCS (ORL-HNS) Section 1 ABOto Written Boards EBEORL-HNS Part 1 FRCS (ORL-HNS) Section 2 UK ENT ST3 National Selection

I want updates on WhatsApp I agree to receive emails and updates.

No spam. Unsubscribe anytime.

Start free 1-week trial View plans Mock papers

Unsubscribe anytime.

Plans

Choose your FRCS (ORL-HNS) Section 1 timeline

All paid buttons below go straight to checkout. Mock papers are not included in subscriptions and are available separately.

New learners can create an account during checkout. Existing learners can log in there.

6 monthsFirst pass + repeat cycles + structured review.

3 monthsConsolidation + focused weak-area repair.

1–2 monthsSprint + high-yield repeats.

Recommended 6 Months

6 Months FRCS (ORL-HNS)

Best for steady coverage and repeat review cycles before Section 1.

£599/ 6 months

Subscribe now Start free trial

Flip for what is included →

Mock papers are not included. Buy mock papers separately.

3 Months

3 Months FRCS (ORL-HNS)

A strong balance for consolidation + weak-area repair.

£449/ 3 months

Subscribe now Start free trial

Flip for what is included →

Mock papers are not included. Mock papers.

2 Months

2 Months FRCS (ORL-HNS)

Focused consolidation to sharpen decision-making quickly.

£349/ 2 months

Subscribe now Start free trial

Flip for what is included →

Mock papers are not included. Mock papers.

1 Month

1 Month FRCS (ORL-HNS)

Final sprint: intensive SBA drilling + fast repeats.

£199/ month

Subscribe now Start free trial

Flip for what is included →

Mock papers are not included. Mock papers.

Go to mock papers Open the app (free questions)

Why OtoPrep

Why OtoPrep for FRCS (ORL-HNS) Section 1?

Tap to flip: better targeting, better retention, calmer revision.

Start free 1-week trial Get 6-month access Open the app

Testimonials

What trainees say

Short, honest feedback from users revising for FRCS (ORL-HNS) Section 1.

“The analytics stopped me wasting time. I could finally see exactly where I was dropping marks and fix it systematically.”

— S.K., ENT ST8 (UK), sitting Section 1

“Timed mock papers changed my pacing completely. Exam day felt familiar because I had trained under the same pressure.”

— J.P., ENT ST7 (UK)

“Best part is the explanations — especially why the wrong answers are wrong. That is where the learning happens.”

— A.R., ENT ST6 (UK)

“The flag-and-repeat loop made revision feel organised. Less panic, more progress.”

— M.T., Trust Grade ENT

FRCS (ORL-HNS) Section 1 FAQ

Quick answers about access, mock papers, subscriptions, and how to use OtoPrep effectively.

Where do I start?

Start with the 5-question preview or the 1-week FRCS free trial. If you already know you want full access, use any paid plan on this page. After activation, study inside the app.

What is the FRCS free trial?

The FRCS free trial gives you 50 questions for 1 week, with account creation handled during checkout. It is the easiest way to test the workflow before choosing a paid plan.

How many questions are in the FRCS (ORL-HNS) Section 1 bank?

The FRCS (ORL-HNS) Section 1 question bank contains >4,200 SBA questions and continues to grow.

Are mock papers included in subscriptions?

No — mock papers are a separate purchase and are not included in subscriptions. Subscriptions cover the question bank, analytics, and repeat cycles.

How do I choose the right plan length?

If you want structured coverage plus repeat review cycles, the 6-month plan is the best runway. If you are closer to the exam, a shorter plan can work well for focused consolidation.

Can I target specific ENT subspecialties?

Yes — you can build custom quizzes by topic/subspecialty and use weak-area targeting to focus on sections that need the most work.

Can I use OtoPrep on my phone or tablet?

Yes — OtoPrep is mobile-friendly, so you can revise on commutes, between cases, or on-call.

How do I buy access?

Use the checkout links on this page. New learners can create an account during checkout; existing learners can log in there. Once activated, study inside the app with the same account.

Is OtoPrep affiliated with the FRCS exam board?

No. OtoPrep is an independent educational platform and is not affiliated with, endorsed by, or sponsored by any examining body. Exam names are used for descriptive purposes only.

Start free 1-week trial View plans Mock papers

Ready to start?

Start with the free trial, jump straight to a plan, or rehearse with full mock papers if you are in the final stretch.

Start free 1-week trial Get 6-month access Mock papers

Trusted by >2,000 ENT trainees • Independent educational resource • Not affiliated with exam boards.

Follow: Instagram · Facebook · LinkedIn · X

FRCS (ORL-HNS) Section 1 question bank — SBAs, analytics, and repeat cycles

Try the SBA style + explanations (FRCS Section 1)

Gauge Your Readiness for the FRCS (ORL-HNS) Section 1 Exam

Review Before Submit

How to use this preview for the best signal

What FRCS (ORL-HNS) Section 1 tests — and how to revise efficiently

Coverage across ENT subspecialties

A Section 1 system: practise → review → repeat (without the noise)

Timed mock papers for Section 1 rehearsal

A faster path to marks than random drilling

Get weekly Section 1 revision tips

Get your free tips + revision plan

Choose your FRCS (ORL-HNS) Section 1 timeline

6 Months FRCS (ORL-HNS)

3 Months FRCS (ORL-HNS)

2 Months FRCS (ORL-HNS)

1 Month FRCS (ORL-HNS)

Why OtoPrep for FRCS (ORL-HNS) Section 1?

What trainees say

FRCS (ORL-HNS) Section 1 FAQ

Ready to start?

Quick Links

Contact Details

E-mail

Phone Number